ASN-FINGOLIMOD CAPSULE
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
18-06-2020
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
FINGOLIMOD (FINGOLIMOD HYDROCHLORIDE)
Tillgänglig från:
ASCEND LABORATORIES LTD
ATC-kod:
L04AA27
INN (International namn):
FINGOLIMOD
Dos:
0.5MG
Läkemedelsform:
CAPSULE
Sammansättning:
FINGOLIMOD (FINGOLIMOD HYDROCHLORIDE) 0.5MG
Administreringssätt:
ORAL
Enheter i paketet:
100
Receptbelagda typ:
Prescription
Terapiområde:
Immunomodulatory Agents
Produktsammanfattning:
Active ingredient group (AIG) number: 0152886001; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2020-06-23
Produktens egenskaper
_Page 1 of 64 _
PRODUCT MONOGRAPH
PR
ASN-FINGOLIMOD
Fingolimod capsules
0.5 mg fingolimod capsules (as fingolimod hydrochloride)
Sphingosine 1-phosphate receptor modulator
Ascend Laboratories Ltd.
35 Nixon Road, Unit 10
Caledon, Ontario
L7E 1K1
Date of Approval:
June 18, 2020
Submission Control No: 231582
_Page 2 of 64 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................25
DRUG INTERACTIONS
..................................................................................................33
DOSAGE AND ADMINISTRATION
..............................................................................36
OVERDOSAGE
................................................................................................................39
ACTION AND CLINICAL PHARMACOLOGY
............................................................40
STORAGE AND STABILITY
..........................................................................................45
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................45
PART II: SCIENTIFIC INFORMATION
...............................................................................46
PHARMACEUTICAL INFORMATION
..........................................................................46
CLINICAL TRIALS
..........................................................................................................47
DETAILED PHARMACOLOGY
.................................
Läs hela dokumentet
